Among the entire population of 401 study patients, 318 were diagnosed with primary stage IV disease (79%, “de novo” stage IV EGFR+ NSCLC, Table 1), while 83 had initially presented with nonmetastatic disease, were treated as shown in Table 2, and developed stage IV EGFR+ NSCLC after subsequent tumor relapse or progression (21%, “secondary” stage IV). Here, EGFR is linked to non-small cell lung carcinoma.